Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label two-cohort safety study of T-DM1 monotherapy in previously treated HER2-positive locally advanced or metastatic breast cancer
CTR20150630Phase 3Active
- Sponsor
- Roche
- Start
- May 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Started May 2016; status: active.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20150630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150630.